Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722341 | 1.00 | NAAA (0.53) | NAAAPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2722626 | 1.00 | NAAA (0.53) | NAAAPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27933978 | 0.90 | PKM (0.49) | NAAAPKMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2724290 | 0.85 | PKM (0.54) | PKMSLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL2724289 | 0.85 | PKM (0.54) | PKMSLC6A2SLC6A4SLC6A3NPC1 | |
| SCHEMBL16708937 | 0.84 | NAAA (0.51) | NAAAGRIN2BNPC1RAB9AKDM1A | |
| SCHEMBL16699888 | 0.84 | NAAA (0.51) | NAAAGRIN2BNPC1RAB9AKDM1A | |
| SCHEMBL2725346 | 0.84 | NAAA (0.51) | NAAAGRIN2BNPC1RAB9AKDM1A | |
| SCHEMBL21065263 | 0.84 | ALDH1A1 (0.51) | NAAANPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL16708938 | 0.84 | ALDH1A1 (0.51) | NAAANPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| CN-103269592-B | Cyclic amine substituted oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME CORP. | 2013-12-12 | — | — | US | disclosed |
| EP-2632269-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103269592-A | Cyclic amine substituted oxazolidinone cetp inhibitor | MERCK SHARP & DOHME | 2013-08-28 | — | — | CN | disclosed |
| WO-2012058187-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | CETP, APOB, MTTP | NAAA 1106/4885PKM 1873/4885SLC6A2 4263/4885 |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | NAAA 4351/4885PKM 239/4885SLC6A2 4698/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | NAAA 4351/4885PKM 239/4885SLC6A2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.